论文部分内容阅读
随着基因分析技术的不断发展,对肿瘤的发病机制以及治疗的研究愈加透彻。依靠传统的组织病理学分类无法充分实现对肿瘤患者的个体化治疗方案选择在制定临床研究的方案时,研究者在考虑病理类型和临床因素之外,还要充分考虑受试个体的基因特征。那么,分子异常改变对肿瘤治疗意义如何,以基因特征为基础的肿瘤临床试验时代离我们到底有多远?本文在此将可能影响肿瘤治疗方向的基因改变类型,以及近年肺癌研究领域一系列基于分子特征的临床试验做一综述。
With the continuous development of gene analysis technology, the research on the pathogenesis and treatment of cancer is more thorough. Relying on traditional histopathological classification can not fully achieve the individualized treatment options for cancer patients in the development of clinical research programs, the researchers consider the pathological type and clinical factors, but also give full consideration to the individual’s genetic characteristics. So, molecular abnormalities change the significance of tumor treatment, based on the genetic characteristics of tumor clinical trials era far away from us in the end of this article will likely affect the direction of tumor treatment of gene mutations, as well as in recent years, a series of lung cancer research based on Molecular characteristics of clinical trials are reviewed.